Compare Amgen, Inc. (AMGN) vs Gogoro Inc (GGR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Gogoro Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Gogoro Inc trades at $3.85 (market cap $77.28M). The key difference: Amgen, Inc. is far larger — about 2537.8× Gogoro Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Gogoro Inc pays none. Which is the better fit depends on your goals.
| AMGN | GGR | |
|---|---|---|
Market Cap | $196.12B | $77.28M |
Sector | Health | Technology |
52-Week High | $388.16 | $7.89 |
52-Week Low | $271.18 | $2.74 |
Enterprise Value | $241.41B | $379.73M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
GGR trades at $3.85, up 1.72% today, but faces significant fundamental challenges with a net loss of $79.97 million in 2025 and negative profit margins. Technical indicators show a bearish trend with mixed signals from oscillators. The company's cash flow remains negative despite operational improvements, while analyst consensus remains neutral with 100% hold ratings.
The outlook remains cautious as GGR struggles with profitability despite revenue stability. Investment opportunity exists in the company's low valuation multiples and battery-swapping technology growth, but risks include persistent losses, negative cash flow, and execution challenges in competitive sustainable mobility markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →
